What are the psychiatric warnings for montelukast?

See the DrugPatentWatch profile for montelukast

What psychiatric symptoms do patients report most often with montelukast?

Montelukast carries a boxed warning for serious neuropsychiatric events. These include agitation, aggression, irritability, depression, anxiety, and suicidal thoughts or actions. The FDA added the warning in 2020 after reviewing reports of completed suicides and severe behavioral changes in adults and children.

How long do these effects usually last?

Most patients see improvement within days to weeks after stopping the drug. Some cases take months to resolve completely, especially if the symptoms had been misdiagnosed as a separate psychiatric disorder.

Why did the FDA add a boxed warning for montelukast?

The decision came after a review of post-marketing data showing consistent reports of serious events, including 82 completed suicides. The agency concluded that the risks outweigh the benefits for many patients with mild asthma or allergic rhinitis.

Can montelukast cause hallucinations or nightmares?

Yes. Nightmares and vivid dreams appear in the prescribing information. Rare cases of hallucinations, both visual and auditory, have been reported to the FDA’s adverse event database.

What happens if someone develops depression on montelukast?

Doctors usually instruct patients to stop the drug immediately. Follow-up care may include mental health evaluation and monitoring for at least week after discontinuation. Some patients require temporary antidepressant treatment.

What alternatives exist if psychiatric warnings keep you from using montelukast?

For mild asthma, inhaled corticosteroids or long-acting beta agonists remain the first-line options. For allergic rhinitis, nasal corticosteroid sprays and antihistamines provide comparable relief without the neuropsychiatric risk.